Condition: Adenoid Cystic Carcinoma · Sinonasal Carcinoma · Sponsor: Eye & ENT Hospital of Fudan University
This prospective, multicenter clinical study aims to evaluate the efficacy and safety of neoadjuvant therapy with MRG003 (Becotatug vedotin) combined with epirubicin in patients with EGFR-positive, unresectable recurrent sinonasal adenoid cystic carcinoma (SNACC). The primary question is whether this combination can achieve a sufficient objective response rate (ORR) to enable subsequent radical surgery or improve disease control.
This description comes directly from the study's public registry record.
Quan Liu, Director · 8615001959681 · liuqent@163.com
Wanpeng Li, mid-level · 8613262856870 · 18879117831@163.com
Always discuss trial participation with your own doctor first.
| Eye & ENT Hospital of Fudan University | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07522879